E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Advanced Systemic Mastocytosis (AdvSM) |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10056453 |
E.1.2 | Term | Aggressive systemic mastocytosis |
E.1.2 | System Organ Class | 100000004851 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to determine ORR of CR/CR with partial recovery of peripheral blood counts (CRh) + PR + CI based on modified IWG-MRT-ECNM consensus response criteria in patients with AdvSM treated with avapritinib. |
|
E.2.2 | Secondary objectives of the trial |
Key secondary objective: assess mean change from baseline in AdvSM-Symptom Assessment Form (AdvSM-SAF) Total Symptom Score (TSS).
Additional secondary objectives:
-Determine time-to-event outcomes including time-to-response (TTR), duration of response (DOR), PFS and OS.
-Assess changes in the individual measures of mast cell (MC) burden:
o Bone marrow (BM) MCs
o Serum tryptase
o KIT mutation burden (eg, D816V) in peripheral blood
o Liver and spleen volume by imaging
-Determine CR/CRh + PR and clinical benefit (CR/CRh + PR + CI + Stable Disease [SD]) based on modified IWG-MRT-ECNM criteria.
-Assess additional PROs using the AdvSM-SAF, including change from baseline in:
o Symptom domain scores
o Individual symptom scores
-Assess changes in QoL measures, including the PGIS and EORTC QLQ-C30
-Assess the safety of avapritinib by AEs, vital signs, ECGs, and laboratory tests
-Assess the PK of avapritinib.
-Correlate avapritinib exposure with safety and efficacy endpoints. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients who are ≥ 18 years of age.
2. Patients must have 1 of the following diagnoses as confirmed by World Health Organization (WHO) diagnostic criteria. Before enrollment, the SSC must confirm the diagnosis of AdvSM (based on Central Pathology Laboratory assessment of BM).
• ASM.
• SM-AHN. The AHN must be myeloid, with additional criteria defined in the protocol.
• MCL.
3. Patients with SM-AHN should have received prior treatment for the AHN component of disease if, in the opinion of the Investigator, such therapy was appropriate.
4. Patient must have a BM biopsy available to be shipped to the Central Pathology Laboratory ≥ 21 days before initiation of study treatment (C1D1).
5. Patient must have at least 1 measurable C-finding per modified IWG-MRT-ECNM, attributed to SM and evaluable for response assessment unless diagnosis is MCL, which does not require a C-finding. Laboratory abnormality C-findings should not be assessed until the required time period from last cytoreductive therapy has been met.
6. Patient must have a serum tryptase ≥ 20 ng/mL.
7. Patients with cytoreductive therapy within the preceding 12 weeks must have discontinued therapy due to disease progression, refractory disease, lack of efficacy, or intolerance.
8. Patient must have symptom management optimized with nonantineoplastic therapies (ie, BSC; eg, H1 and H2 blockers). Dose must be stable for ≥ 14 days before C1D-8.
9. If the patient is receiving corticosteroids, the dose must be ≤ 20 mg/d prednisone or equivalent and dose must be stable for ≥ 14 days before C1D-8.
10. Patient has an Eastern Cooperative Oncology Group Performance Status of 0 to 3.
11. Patient must give written informed consent. |
|
E.4 | Principal exclusion criteria |
1. Patient has received prior treatment with avapritinib.
2. Patient has received any cytoreductive therapy (including midostaurin and other TKIs, hydroxyurea, azacitidine) or an investigational agent less than 14 days, and for cladribine, interferon alpha, pegylated interferon and any antibody therapy (eg, brentuximab vedotin) less than 28 days before obtaining screening BM biopsy for this study.
3. Patient has received prior radiotherapy within 14 days before the screening BM biopsy, unless given to palliate specific sites of disease (eg, bone lesion).
4. Patient received any hematopoietic growth factor within 14 days of screening BM biopsy.
5. Patient requires therapy with a concomitant medication that is a strong inhibitor, strong inducer, or moderate inducer of CYP3A4.
6. Patient has had a major surgical procedure within 14 days of the first dose of study drug. Surgical procedures such as central venous catheter placement, BM biopsy, and feeding tube placement are considered minor surgical procedures.
7. Patient is a candidate for allogeneic hematopoietic stem cell transplantation for treatment of SM, in the opinion of the Investigator.
8. Patient has eosinophilia and known positivity for the FIP1L1-PGDFRA fusion, unless the patient has demonstrated relapse or PD on prior imatinib therapy. Patients with eosinophilia (> 1.5 × 10^9/L), who do not have a detectable KIT D816 mutation, should be tested for a PDGFRA fusion mutation by fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR).
9. Patient has history of another primary malignancy that has been diagnosed or required therapy within 3 years before the first dose of study drug. The following are exempt from the 3-year limit: completely resected basal cell and squamous cell skin cancer, curatively treated localized prostate cancer, and completely resected carcinoma in situ of any site.
10. Patient meets any of the following laboratory criteria:
o AST or ALT > 3.0 × ULN; no restriction if due to suspected liver infiltration by MCs.
o Bilirubin > 1.5 × ULN; no restriction if due to suspected liver infiltration by MCs or Gilbert’s disease.
o Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m^2 or creatinine clearance calculated by Cockcroft-Gault equation < 40 mL/min.
11. Patient has a QT interval corrected using Fridericia’s formula (QTcF) > 450 msec.
12. Patient has a history of a seizure disorder (eg, epilepsy) or requirement for antiseizure medication.
13. Patient has a history of a cerebrovascular accident or transient ischemic attacks within 1 year before the first dose of study drug.
14. Patient has a known risk or recent history (within the preceding 1 year) of intracranial bleeding (eg, brain aneurysm).
15. Patient has a primary brain malignancy or metastases to the brain.
16. Patient has clinically significant, uncontrolled cardiovascular disease, including Grade III or IV congestive heart failure according to the New York Heart Association classification; myocardial infarction or unstable angina within the previous 6 months; clinically significant, uncontrolled arrhythmias; or uncontrolled hypertension.
17. Patient is unwilling or unable to comply with scheduled visits, drug administration plan, laboratory tests, or other study procedures and study restrictions.
18. Female patients who are unwilling, if not postmenopausal or surgically sterile, to abstain from sexual intercourse or employ highly effective contraception during the study drug administration period and for at least 30 days after the last dose of study drug. Men who are unwilling, if not surgically sterile, to abstain from sexual intercourse or employ highly effective contraception during the study drug administration period and for at least 90 days after the last dose of study drug.
19. Female patients who are pregnant, as documented by a serum beta human chorionic gonadotropin (β-hCG) pregnancy test consistent with pregnancy obtained within 15 days before the first dose of study drug. Women with β-hCG values that are within the range for pregnancy but are not pregnant (false-positives) may be enrolled with written approval of the Sponsor after pregnancy has been excluded. Women of nonchildbearing potential (ie, women who are postmenopausal or have undergone hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) do not require a serum β-hCG pregnancy test.
20. Women who are breast feeding.
21. Patient has a prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the opinion of the Investigator, could affect the safety of the patient, alter the absorption, distribution, metabolism, or excretion of the study drug, or impair the assessment of study results. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
ORR (CR/CRh + PR + CI) based on modified IWG-MRT-ECNM criteria, confirmed 12 weeks after initial response. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At C1D15, C2D1, C3D1, C7D1 and C11D1 and then every 6 cycles. Also performed 12 weeks (± 4 weeks) after documentation of CR or PR to confirm response and 4 weeks after SM and/or AHN PD or clinical progression to confirm PD. Performed at EOT if patient discontinues for reasons other than PD or initiation of alternative cytoreductive therapy. |
|
E.5.2 | Secondary end point(s) |
• Mean change from baseline in AdvSM-SAF TSS.
Additional secondary endpoints:
• Time-to-event outcomes including TTR, DOR, PFS, and OS.
• Changes in BM MCs, serum tryptase, KIT mutation burden (eg, D816V) in PB, and liver and spleen volume by imaging.
• CR/CRh + PR and clinical benefit (CR/CRh + PR + CI + SD) based on modified IWG-MRT-ECNM criteria.
• Mean change from baseline in AdvSM-SAF domain and individual symptom scores.
• Changes in PGIS and EORTC QLQ-C30 (global health status, functional scales, and symptom scales/items) score.
• Safety of avapritinib, as assessed by AEs, changes in vital signs, ECGs, and laboratory testing.
• PK of avapritinib.
• Correlations between avapritinib exposure and safety and efficacy endpoints. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
• AdvSM-SAF: daily from C1D7 to C17 or until patient discontinuation
• OS: until death or loss to F/U
• BM biopsy/aspirate: screening, C3D1, C7D1, C11D1, every 6 cycles, EOT, PD F/U
• Serum tryptase, liver/spleen imaging: screening, C1D15, C2D1, C3D1, C7D1, C11D1, every 6 cycles, EOT, PD F/U
• KIT D816V mutant allele burden: screening, C1D1, C1D15, C2D1, C3D1, C7D1, C11D1, every 6 cycles, EOT, PD F/U
• Response: C1D15, C2D1, C3D1, C7D1, C11D1, every 6 cycles, EOT, PD F/U
• PGIS, EORTC QLQ-C30: each visit through C17, EOT
• AE: from C1D1 to Safety F/U
• Vital signs & ECG: each visit through EOT
• Lab: screening, each visit from C1D15 to EOT, PD F/U
• PK: C1D1, C2D1, C3D1, C5D1 predose and any 1 time point between 1 and 8 hrs postdose, C1D15 predose, 1, 4 and 6 to 8 hrs postdose |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 14 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Denmark |
France |
Germany |
Italy |
Netherlands |
Norway |
Poland |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study is defined as the time that the last patient completes his/her last visit (LPLV), including assessments performed as part of follow-up for OS, if the patient enters the OS follow-up period of the study. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 6 |